PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Am Acad Child Adolesc Psychiatry. Author manuscript; available in PMC Apr 2, 2009.
Published in final edited form as:
PMCID: PMC2664646
NIHMSID: NIHMS95008
Autism-Spectrum Disorders and Childhood Onset Schizophrenia: Clinical and Biological Contributions to a Relationship Revisited
Judith Rapoport, M.D., Alex Chavez, B.S., Deanna Greenstein, Ph.D., Anjene Addington, Ph.D., and Nitin Gogtay, M.D.
Child Pychiatry Branch, National Institute of Mental Heath (NIMH), Bethesda, MD
Correspondence: Nitin Gogtay, M.D. Child Psychiatry Branch, Building 10, Rm 3N202, 10 Center Drive, MSC 1600, Bethesda, MD 20892, Tel: (301) 435 4494, Fax: (301) 402 7160, Email: gogtayn/at/mail.nih.gov
Objective
To highlight emerging evidence for clinical and biological links between autism/Pervasive Developmental Disorder (PDD) and schizophrenia, with particular attention to childhood onset schizophrenia (COS).
Method
Clinical, demographic and brain developmental data from the NIMH (and other) COS studies, and selected family, imaging and genetic data from studies of autism, PDD and schizophrenia were reviewed.
Results
In the two large studies that have examined this systematically, COS is preceded by and comorbid with Pervasive Developmental Disorder in 30%-50% of cases. Epidemiologic and family studies find association between the disorders. Both disorders have evidence of accelerated trajectories of anatomic brain development at ages near disorder onset. A growing number of risk genes and/or rare small chromosomal variants (micro-deletions or duplications) are shared by schizophrenia and autism.
Conclusion
Biological risk does not closely follow DSM phenotypes and core neurobiological processes are likely common for subsets of these two heterogeneous clinical groups. Long-term prospective follow up of autistic populations, and greater diagnostic distinction between schizophrenia spectrum and autism spectrum disorders in adult relatives are needed.
Keywords: Schizophrenia, Childhood, Autism
The separation of autism from childhood-onset psychoses, particularly schizophrenia, was an important advance for the study of childhood psychopathology. The lack of this distinction in DSM II1 evolved to a delineation of autism/pervasive developmental disorder (PDD) as a separate category from early onset schizophrenia in DSM III2 based on clinical, familial and follow-up studies. DSM III-R, IV and DSM IV-TR further elaborated the PDD category3, 4. This distinction enabled decades of research validating different patterns with respect to familial, brain imaging, and genetic risk5-8. Clinically, this has been a basic and self evident distinction as age of onset, differential diagnosis, and treatment of the two conditions differed 9. This review supports the clinical utility of the distinction, but systematic studies of childhood onset schizophrenia (COS) show high comorbidity between COS and PDD, and the emergence of some common family, genetic and imaging findings warrants further review and comment.
COS is defined as onset of psychosis before age 13 and is a rare and severe form of schizophrenia. Onset is usually after age 7, positive and negative symptoms are prominent, and prognosis is poor10. In contrast, autism is defined by abnormal behavior in the spheres of communication, social relatedness, and stereotyped behaviors within the first three years of life. The broader category, Pervasive Developmental Disorder (subsuming Autism, Rett Syndrome, Asperger's Syndrome and Childhood Disintegrative Disorder) has a residual category, PDD-NOS (not otherwise specified), which is based on the social relatedness symptoms for autism but allows for different age of onset, and fewer other spheres. Thus, DSM IV-TR PDD-NOS requires failure to develop appropriate reciprocal social behaviors as a necessary defining feature11. Inevitably, there will be further subdivisions and hopefully brain imaging and genetic studies will provide clues about how to do this. One particular category –Multiple Complex Developmental Disorder (MCDD), discussed below, is a possible bridge with schizophrenia 12-14.
When advances in psychiatry permitted the field to conceptualize psychotic disorders and developmental disorders as distinct, the phenomena of PDD and COS as comorbid disorders could be explored. In the DSM-II, autism was referred to as schizophrenia, childhood type, and was characterized by “atypical and withdrawn behavior,” “failure to develop identity separate from the mother's,” and “general unevenness, gross immaturity and inadequacy in development.” However, important post DSM-II work conducted by Kolvin and others focused on the contrast between very early onset schizophrenia (with typical onset after age 7) 15 and earlier onset autism. This research was influential in making the distinction between childhood onset schizophrenia and autism in the DSM III. The phenomenology of childhood onset schizophrenia was described by Kolvin et al. in a groundbreaking study of 33 British children, of whom 12 had onset before age 13.16 In addition, the researchers stressed the severity and frequency of prepsychotic developmental disorders in COS.
The observations of Kolvin and colleagues have been replicated in virtually every study of early onset schizophrenia with findings of developmental abnormalities primarily for communication, motor abnormalities and/or social relatedness 10, 17. For example, an early report from the UCLA COS study found that 39% of a sample of 33 patients had symptoms of autism years before onset of schizophrenia18. Since the initial 1988 report, the UCLA group has examined an additional 52 COS probands using the K-SADS-E structured diagnostic interview [16]. Of these, 28 (55%) had histories meeting DSM III-R criteria for autism or PDD (Dr. Robert Asarnow personal communication May 2008). The largest study to date of COS now includes 101 children and adolescents with onset of DSM IV defined schizophrenia before age 13. Of these, one (1%) met criteria for comorbid autism, 2 (2%) for Asperger's Syndrome and 25 (25%) for PDD-NOS, making for a total of 28% with comorbid autism or autism spectrum disorder (ASD) (unpublished data, Nitin Gogtay M.D.). These diagnoses were made by both screening questionnaire and agreement by two board certified child psychiatrists in recognition of the pitfalls of diagnosis by screening instrument alone 19. PDD-NOS was a persisting and stable diagnosis in these cases, with onset in the first five years of life, while the onset of psychotic symptoms occurred typically 3-5 years later.
Premorbid developmental disturbance in schizophrenia is hardly a new concept and schizophrenia itself is widely regarded as a neurodevelopmental disorder 20. Large cohort studies of the antecedents of schizophrenia have documented subtle developmental delays long predating the onset of psychosis 21 22-24. A prospective pediatric population study found a relatively specific pattern of childhood developmental disturbance consisting of impairments in neuromotor, receptive language, and cognitive development that were seen only among children later diagnosed as having schizophreniform disorder25. Developmental impairments also predicted self-reported psychotic symptoms at age 11. These impairments were termed “pan developmental dysmaturation,” more consistent with the findings of the (adult onset) schizophrenia cohort studies consisting primarily of developmental lags. These too are common in the NIMH COS cohort, and 39 patients (39%) exhibited one or more of these non-PDD developmental disturbances.
These data are shown in Table I.
Thus two sets of somewhat different early developmental disturbances are seen. One set includes members of the COS sample who met criteria for a DSM-IV-TR PDD-NOS (n=28) and another set (n=39) who had language, motor or social impairments stemming from impulsivity or anxiety. Of note, the PDD + COS subjects' demographic patterns follow those reported in the literature for PDD generally, as they are primarily male (p = 0.04) and non-African American (p = 0.02) All had failure to develop reciprocal social behaviors as their defining common characteristic, which was temporally and clinically distinct from their later development of psychotic symptoms.
In the ongoing NIMH study to date, 263 family members have been evaluated with structured interviews and parents were administered the Autism Screening Questionnaire (ASQ) for siblings. The average ASQ score was higher among unaffected siblings of children with comorbid PDD/COS than among unaffected siblings of COS patients without PDD, as consistent with previous reports 26. This finding implies that PDD symptoms are heritable and may serve as trait markers even in unaffected individuals.
Several models have been proposed to account for psychiatric comorbidity27. As Krueger and Markon have reviewed, comorbidity may reflect causality between the conditions, alternate forms of the same disorder, unique subgroups that share both attributes, or different manifestations of a single or correlated underlying liability. The only one of these models with some research-based links to schizophrenia comes from a subgroup of PDD–NOS defined as Multiple Complex Developmental Disorder (MCDD). MCDD is observed in children ages 12-18 years and is characterized by impaired sensitivity to social stimuli, as well as thought disorder, bizarre and disorganized thinking, inappropriate affect and mood lability 12, 14. Although less disturbed than children with autism with respect to social interaction, communication and stereotyped and rigid behaviors, children with MCDD were more disturbed with respect to flagrant thought disorder, anxieties and aggression14, 28. The diagnosis of very early onset schizophrenia was considered by the initiators of the MCDD construct, but the relative frequency of the MCDD group suggested it was a broader group from which schizophrenia might emerge. Moreover, follow up studies of MCDD indicate that by adolescence and young adulthood, 22% and 64% respectively, convert to (some form of) psychosis29 or resembled subjects in psychosis high-risk groups 13. The MCDD constellation remains relatively ignored by clinicians in the United States as almost all work on this has been carried out in the Netherlands.
The growing literature on brain imaging abnormalities in COS will not be reviewed here. In autism, the best agreed upon finding is increased head size/total brain volume seen in the first three years of age based on cross sectional studies 30, 31. This brain overgrowth that precedes or coincides with the appearance of signs and symptoms of autism suggests that it may be a fundamental aspect of the pathologic process32. There remains controversy, however, as to whether the brain anatomic developmental curves for autistic and control groups remain parallel or converge in later years 31, 33 because at later ages the findings are inconsistent34 The diffuse network of brain regions affected has shifted attention to more widespread mechanisms at the neuronal level.
There is little overlap between the reported anatomic brain abnormalities in autism and COS. COS studies show a striking loss of cortical gray matter (GM) in early ages that progresses through adolescent years, which appears to be an exaggeration of the normal pattern of cortical brain development 35, 36. This global GM loss in COS also declines with age, eventually circumscribed only to prefrontal and superior temporal cortices resembling the typical adult schizophrenia pattern seen by age 24 37. The reason for what on first glance looks to be “normalization” of COS brain scans with age, is that the healthy controls “catch up” with the patients with respect to late adolescent cortical thinning.
Although limited by lack of prospective and fetal studies, at this point it appears that in autism there is an acceleration or excess of early postnatal brain development (1-3 years), whereas in COS there is exaggeration of the brain maturation processes of childhood and early adolescence (10-16 yrs). Both could be seen as “increased gain” of general developmental processes, albeit at different stages; both patterns could also be seen as an abnormal “shift to the left” with respect to age compared to normal brain development, with autism showing initial overgrowth and COS showing greater “pruning down” of the cortex in early and middle parts of the trajectory; both accelerations normalizing with age.
There are numerous direct and indirect genetic data linking autism and schizophrenia38-41. Specifically, various candidate gene and linkage studies and expression studies utilizing postmortem brain samples, as well as studies of copy number variants (CNVs) in schizophrenia, have yielded a handful of genetic associations that have also been reported for autism 42, 43. Large alterations in chromosme region or number are increased in COS44. Genomic microduplications and deletions or CNVs underlie many serious illnesses and neurodevelopmental syndromes45. Selected results representing these emerging overlapping genetic findings are summarized in Table II, and given that a comprehensive review of this rapidly growing literature is beyond the scope of this paper, we highlight some of the most compelling findings below.
Table II
Table II
Genomic regions and genes associated with both autism and schizophrenia
The VCFS (chromosome 22q11) deletion shows high rates of childhood autism spectrum disorders (30 of 60: 50%) and psychotic symptoms (16 of 60: 26.7%) 42. Although screening of 103 autistic subjects showed no cases of 22q.11 deletion 46, given that the rate of 22q11 deletion in the general population (1/4000) and in schizophrenia (0.4%) is low, this negative finding is not surprising. Hemizygous deletion in the 22q11 region is a highly nonspecific risk factor for a number of neurodevelopmental disorders (speech and language particularly) as well as other disorders such as OCD. Nonetheless, the 22q11 deletion is the third largest genetic predictor of schizophrenia (25 times the population risk), behind having an affected monozygotic twin or two affected parents. The rate of 4% observed in the NIMH COS cohort is significantly higher than the 0.4% observed in unselected adult onset samples47.
The approximately 500kb microdeletion and microduplication event on 16p11.2 now reported in approximately 1% of cases of autism43, 48, 49, some de novo and some inherited, was observed also in 2 of the NIMH COS patients. It was also reported in a family with siblings with mild mental retardation 50. Like the region on 22q11, CNVs in the 16p11.2 region may prove to be a similarly nonspecific risk factor for various neurodevelopmental disturbances. CNVs in both the 22q11 and 16p11 regions will likely be among the more commonly observed risk factors in that the genomic architecture in these regions are flanked by areas of segmental duplications which are more prone to genomic rearrangements during meiosis.
Deletions, disruptions and missense mutations in Neurexin 1 (NRXN1) have been reported recently in several cases with autism48, 51-54, and two cases with schizophrenia 43, 55, 56. Altogether, these findings provide evidence that rare (and common) variants at the NRXN1 locus likely predispose individuals to autism, schizophrenia, or both.
Finally, several recent publications have reported increased rates of rare CNVs in different samples of schizophrenia and autism48, 57, 58. Interestingly, within our COS sample, the presence of a large chromosomal abnormality and/or rare CNV that disrupts a gene was much more common among the COS patients with prior history of any developmental disturbance: 28 of 63 (44%) as compared to 4 out of 29 (14%) with a “clean” history of premorbid development (p=0.005). Taken together, rare structural variants may account for a large proportion of the variance in disease etiology and are likely to uncover many new candidate regions and genes.42, 59, 60
While there are intriguing genetic links between schizophrenia and autism spectrum disorders, these do not support any model in themselves, except to suggest the probability that many individually rare genetic abnormalities affect common pathways containing hundreds of genes that effect neuronal development and regulation. The commonality of several genes for different syndromes, however, presents a chance to link the disorders at a molecular level. Several fundamental questions of mechanism remain to be explored. For example, genetic pleiotropy (multiple phenotypic effects from a single gene) is well established in neurodevelopmental disorders 61, leaving open the question whether different mutations in the same genes, modifying genes, environmental influences, or perhaps stochastic events, determine which disorder is manifest.
The subtle developmental delays that are seen in large prospective cohort studies of adult onset schizophrenia are seen in exaggerated form in childhood onset cases10, 62. Early onset schizophrenia has also shown strong comorbidity with pervasive developmental disorders in two of the three large studies in which this was measured systematically, although until now this has received less attention. Comorbidity is the most straightforward way to describe such findings, but as noted above, this association does not imply any one model, and both causal or independent associations are possible.
While associations between these conditions are not striking to the treating clinician, there are new data to indicate that in fact autism and schizophrenia are more likely to be seen in the same patients 63 and families. A link between the two disorders has been suggested in a handful of studies in adult populations 13, 64-66, and epidemiologic and larger patient-population data show familal schizophrenia-like psychosis to be a risk factor for (narrowly defined) autism 67. That these findings are not seen in clinical practice may be explained by the heterogeneity of these populations, which dilutes the effects in smaller samples. Alternately, under the current diagnostic hierarchy (in which autism and schizophrenia are mutually exclusive) if a person develops autism as a young child, they may be unlikely to receive a diagnosis of schizophrenia later on, even if new symptoms emerge.
Various explanations for a schizophrenia-autism association are possible. Developmental disorders per se may be risk factors for schizophrenia68, and indicators of early fetal disturbance such as minor physical anomalies have been found increased in both autism and schizophrenia69. It is of interest that the rare chromosomal abnormalities and/or copy number variants found in the NIMH COS population58 are most common in patients with either the “delay” type or the PDD premorbid disturbances than in those with “clean” prior histories and may be related more to the early developmental disturbance than to schizophrenia per se. This is being tested in a current study.
We posit a pathophysiologic link with disturbance in brain developmental timing for both disorders at ages approximating the onset of these disorders. The abundant genetic links do not support a model in which one disorder causes the other. Since each disorder exists primarily in separate form, i.e. most cases of autism\PDD or schizophrenia are not comorbid, these findings are most likely to help sort out the almost certain heterogeneity for both disorders that has been problematic for genetic research. The nonspecificity of the identified variants also provides an opportunity for understanding the disorders at a molecular level. If the same genes, for example, cause both disorders, this could be because of various genetic or environmental modifying factors producing a different timing or mode of action that in turn leads to a particular phenotype. Alternatively, if different genes are implicated in the same phenotype then there would be great interest in seeing what underlying neurobiological pathways might in common be affected by these genes. These strategies will be of crucial importance for future clinical neuroscience research.
In summary, two disorders that have been distinguished since DSM-III, are again linked using newer research methods. It is likely that genetic studies in childhood disorders will increasingly implicate patterns of brain developmental disturbance leading us to group disorders in novel ways. This is being tested in a current study of non schizophrenic children with similar developmental delays. It is anticipated that this group too will be enriched with CNVs and it may be that these developmental delays are in themselves a risk for psychosis at any age. Epidemiologic studies of schizophrenia need to more carefully screen relatives for PDD/ASD and a follow up of larger samples of patients with autism participating in genetic studies would be particularly informative in terms of the likelihood of psychosis onset, and predictors of this outcome.
There are no immediate clinical implications for these findings. Shortcomings of DSM IV include frequent use of NOS diagnoses and high rates of comorbidity. The data presented for PDD-NOS and COS in this review show how clinical phenotypes do not relate simply to genetic risk factors. The linking of autism and schizophrenia in family studies does not fit with typical clinical experience. An immediate practical implication of this report is that training of adult psychiatrists needs to include the diagnosis of adults with autism and autism spectrum/PDD to better discriminate milder forms of autism spectrum and schizophrenia spectrum disorders for future family studies. Finally, sorting out what exactly we mean by genetic and syndromal heterogeneity will be a cornerstone of future clinical neuroscience.
Acknowledgments
All the support for this work has been from the NIMH intramural program.
1. American Psychiatric Association. Committee on Nomenclature and Statistics. Diagnostic and statistical manual of mental disorders. 2d. Washington: 1968.
2. American Psychiatric Association., American Psychiatric Association. Task Force on Nomenclature and Statistics. Quick reference to the diagnostic criteria from DSM-III. Washington: American Psychiatric Assn; 1980.
3. Association AP. Diagnostic and Statistical Manual of Psychiatric Disorders. 3rd. Washington, DC: American Psychiatric Press Inc.; 1987.
4. Rapoport J, Ismond D. DSM-III Training Guide for Diagnosis of Childhood Disorders. New York: Brunner Mazel, Inc.; 1984.
5. Rutter M. The Emanuel Miller Memorial Lecture 1998. Autism: two-way interplay between research and clinical work. J Child Psychol Psychiatry. 1999 Feb;40(2):169–188. [PubMed]
6. Berument SK, Rutter M, Lord C, Pickles A, Bailey A. Autism screening questionnaire: diagnostic validity. Br J Psychiatry. 1999 Nov;175:444–451. [PubMed]
7. Folstein SE, Rosen-Sheidley B. Genetics of autism: complex aetiology for a heterogeneous disorder. Nat Rev Genet. 2001 Dec;2(12):943–955. [PubMed]
8. Folstein SE, Rutter ML. Autism: familial aggregation and genetic implications. J Autism Dev Disord. 1988 Mar;18(1):3–30. [PubMed]
9. Rutter M, Taylor E. Child and Adolescent Psychiatry. London: Blackwell; 2002.
10. Hollis C, Rapoport J. Child and Adoelscent Schizophrenia. In: Weinberger D, Harrison P, editors. Schizophrenia. 3rd. London: Blackwell; 2008.
11. Association AP. Diagnostic and Statistical Manueal of Mental Disorders. 4th Edition - Text Revision ed. Washington, DC: American Psychiatric Association; 2000.
12. Demb HB, Noskin O. The use of the term Multiple Complex Developmental Disorder in a diagnostic clinic serving young children with developmental disabilities: A report of 15 cases. Mental Health Aspects of Developmental Disabilities. 2001 Apr-Jun;4(2):4960.
13. Sprong M, Becker HE, Schothorst PF, et al. Pathways to psychosis: a comparison of the pervasive developmental disorder subtype Multiple Complex Developmental Disorder and the “At Risk Mental State” Schizophr Res. 2008 Feb;99(13):38–47. [PubMed]
14. de Bruin EI, de Nijs PF, Verheij F, Hartman CA, Ferdinand RF. Multiple complex developmental disorder delineated from PDD-NOS. J Autism Dev Disord. 2007 Jul;37(6):1181–1191. [PubMed]
15. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36:980–988. [PubMed]
16. Kolvin I, Ounsted C, Humphrey M, McNay A. Studies in the childhood psychoses. II. The phenomenology of childhood psychoses. Br J Psychiatry. 1971 Apr;118(545):385–395. [PubMed]
17. Alaghband-Rad J, McKenna K, Gordon CT, et al. Childhood-onset schizophrenia: the severity of premorbid course. J Am Acad Child Adolesc Psychiatry. 1995 Oct;34(10):1273–1283. [PubMed]
18. Watkins JM, Asarnow RF, Tanguay PE. Symptom development in childhood onset schizophrenia. J Child Psychol Psychiatry. 1988 Nov;29(6):865–878. [PubMed]
19. Reaven J, Hepburn S, Ross RG. Use of ADOS and ADI-R in children with psychosis: Importance of clinical judgement. Clinical Child Psychology and Psychiatry. 2008;13:81–84. [PubMed]
20. Weinberger D. Implications of normal brain development for the pathogenesis of schizophrena. Archives of General Psychiatry. 1987;44:660–669. [PubMed]
21. Jones P, Rodgers B, Murray R, Marmot M. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet. 1994 Nov 19;344(8934):1398–1402. [PubMed]
22. Done DJ, Crow TJ, Johnstone EC, Sacker A. Childhood antecedents of schizophrenia and affective illness: social adjustment at ages 7 and 11 [see comments] BMJ. 1994;309:699–703. [PMC free article] [PubMed]
23. Done DJ, Crow TJ, Johnstone EC, Sacker A. Childhood antecedents of schizophrenia and affective illness: social adjustment at ages 7 and 11. Bmj. 1994 Sep 17;309(6956):699–703. [PMC free article] [PubMed]
24. Isohanni M, Jones P, Kemppainen L, et al. Childhood and adolescent predictors of schizophrenia in the Northern Finland 1966 birth cohort--a descriptive life-span model. Eur Arch Psychiatry Clin Neurosci. 2000;250(6):311–319. [PubMed]
25. Cannon M, Caspi A, Moffitt TE, et al. Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. Arch Gen Psychiatry. 2002 May;59(5):449–456. [PubMed]
26. Sporn AL, Addington AM, Gogtay N, et al. Pervasive developmental disorder and childhood-onset schizophrenia: comorbid disorder or a phenotypic variant of a very early onset illness? Biol Psychiatry. 2004 May 15;55(10):989–994. [PubMed]
27. Krueger RF, Markon KE. Reinterpreting Comorbidity: A Model-Based Approach to Understanding and Classifying Psychopathology. Ann Rev Clin Psychol. 2006;2:111–133. [PMC free article] [PubMed]
28. Buitelaar JK, van der Gaag RJ. Diagnostic rules for children with PDD-NOS and multiple complex developmental disorder. Journal of Child Psychology and Psychiatry. 1998 Sep;39(6):911–919. [PubMed]
29. van Engeland H, Van der Gaag RJ. MCDD in childhood: a precursor of schizophrenic spectrum disorders. Schizophrenia Research. 1994;11:197–207.
30. Courchesne E, Carper R, Akshoomoff N. Evidence of brain overgrowth in the first year of life in autism. Jama. 2003 Jul 16;290(3):337–344. [PubMed]
31. Hazlett HC, Poe M, Gerig G, et al. Magnetic resonance imaging and head circumference study of brain size in autism: birth through age 2 years. Arch Gen Psychiatry. 2005 Dec;62(12):1366–1376. [PubMed]
32. Williams DL, Minshew NJ. Understanding autism and related disorders: what has imaging taught us? Neuroimaging Clin N Am. 2007 Nov;17(4):495–509. ix. [PMC free article] [PubMed]
33. Hazlett HC, Poe MD, Gerig G, Smith RG, Piven J. Cortical gray and white brain tissue volume in adolescents and adults with autism. Biol Psychiatry. 2006 Jan 1;59(1):1–6. [PubMed]
34. Mosconi M, Zwaigenbaum L, Piven J. Structural MRI in autism: findings and future directions. Clinical Neuroscience Research. 2006;6:135–144.
35. Thompson PM, Hayashi KM, Sowell E, et al. Mapping cortical change in Alzheimer's disease, brain development, and schizophrenia. NeuroImage. 2004;23:S2–S18. [PubMed]
36. Gogtay N, Giedd JN, Lusk L, et al. Dynamic mapping of human cortical development during childhood through early adulthood. Proc Natl Acad Sci U S A. 2004 May 25;101(21):8174–8179. [PubMed]
37. Greenstein D, Lerch J, Shaw P, et al. Childhood onset schizophrenia: cortical brain abnormalities as young adults. J Child Psychol Psychiatry. 2006 Oct;47(10):1003–1012. [PubMed]
38. Chagnon YC. Shared susceptibility region on chromosome 15 between autism and catatonia. Int Rev Neurobiol. 2006;72:165–178. [PubMed]
39. Di Cristo G. Development of cortical GABAergic circuits and its implications for neurodevelopmental disorders. Clin Genet. 2007 Jul;72(1):1–8. [PubMed]
40. Fatemi SH. Reelin glycoprotein in autism and schizophrenia. Int Rev Neurobiol. 2005;71:179–187. [PubMed]
41. Gordon CT, Krasnewich D, White B, Lenane M, Rapoport JL. Brief report: translocation involving chromosomes 1 and 7 in a boy with childhood-onset schizophrenia. J Autism Dev Disord. 1994 Aug;24(4):537–545. [PubMed]
42. Vorstman JA, Morcus ME, Duijff SN, et al. The 22q11.2 deletion in children: high rate of autistic disorders and early onset of psychotic symptoms. J Am Acad Child Adolesc Psychiatry. 2006 Sep;45(9):1104–1113. [PubMed]
43. Weiss LA, Shen Y, Korn JM, et al. Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med. 2008 Feb 14;358(7):667–675. [PubMed]
44. Rapoport JL, Addington AM, Frangou S, Psych MR. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry. 2005 May;10(5):434–449. [PubMed]
45. Lee JA, Lupski JR. Genomic rearrangements and gene copy-number alterations as a cause of nervous system disorders. Neuron. 2006 Oct 5;52(1):103–121. [PubMed]
46. Ogilvie CM, Moore J, Daker M, Palferman S, Docherty Z. Chromosome 22q11 deletions are not found in autistic patients identified using strict diagnostic criteria. IMGSAC. International Molecular Genetics Study of Autism Consortium. Am J Med Genet. 2000 Feb 7;96(1):15–17. [PubMed]
47. Sporn A, Addington A, Reiss AL, et al. 22q11 deletion syndrome in childhood onset schizophrenia: an update. Mol Psychiatry. 2004 Mar;9(3):225–226. [PubMed]
48. Marshall CR, Noor A, Vincent JB, et al. Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet. 2008 Feb;82(2):477–488. [PubMed]
49. Kumar RA, KaraMohamed S, Sudi J, et al. Recurrent 16p11.2 microdeletions in autism. Hum Mol Genet. 2008 Feb 15;17(4):628–638. [PubMed]
50. Ghebranious N, Giampietro PF, Wesbrook FP, Rezkalla SH. A novel microdeletion at 16p11.2 harbors candidate genes for aortic valve development, seizure disorder, and mild mental retardation. Am J Med Genet A. 2007 Jul 1;143(13):1462–1471. [PubMed]
51. Kim HG, Kishikawa S, Higgins AW, et al. Disruption of neurexin 1 associated with autism spectrum disorder. Am J Hum Genet. 2008 Jan;82(1):199–207. [PubMed]
52. Zahir FR, Baross A, Delaney AD, et al. A patient with vertebral, cognitive and behavioural abnormalities and a de novo deletion of NRXN1{alpha} J Med Genet. 2007 Dec 5; [PubMed]
53. Consortium TAGP. Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nature Genetics. 2007;39:319–328. [PubMed]
54. Feng J, Schroer R, Yan J, et al. High frequency of neurexin 1beta signal peptide structural variants in patients with autism. Neurosci Lett. 2006 Nov 27;409(1):10–13. [PubMed]
55. Zoghbi H. Postnatal Neurodevelopmental Disorders: Meeting at the synapse? Science. 2003 Oct 31;302:826–830. [PubMed]
56. Kirov G, Gumus D, Chen W, et al. Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. Hum Mol Genet. 2008 Feb 1;17(3):458–465. [PubMed]
57. Sebat J, Lakshmi B, Malhotra D, et al. Strong association of de novo copy number mutations with autism. Science. 2007 Apr 20;316(5823):445–449. [PMC free article] [PubMed]
58. Walsh T, McClellan J, McCarthy S, et al. Rare Structural Variants Disrupt Multiple Genes in Neurodevelopmental Pathways. Science. 2008 [PubMed]
59. Vorstman JA, Staal WG, van Daalen E, van Engeland H, Hochstenbach PF, Franke L. Identification of novel autism candidate regions through analysis of reported cytogenetic abnormalities associated with autism. Mol Psychiatry. 2006 Jan;11(1) 1:18–28. [PubMed]
60. Kilpinen H, Ylisaukko-Oja T, Hennah W, et al. Association of DISC1 with autism and Asperger syndrome. Mol Psychiatry. 2007 June 19;
61. Zoghbi HY. Postnatal neurodevelopmental disorders: meeting at the synapse? Science. 2003 Oct 31;302(5646):826–830. [PubMed]
62. Hollis C. Child and adolescent (juvenile onset) schizophrenia. A case control study of premorbid developmental impairments. Br J Psychiatry. 1995 Apr;166(4):489–495. [PubMed]
63. Stahlberg O, Soderstrom H, Rastam M, Gillberg C. Bipolar disorder, schizophrenia, and other psychotic disorders in adults with childhood onset AD/HD and/or autism spectrum disorders. J Neural Transmission. 2004;111:891–902. [PubMed]
64. Stahlberg O, Soderstrom H, Rastam M, Gillberg C. Bipolar disorder, schizophrenia, and other psychotic disorders in adults with childhood onset AD/HD and/or autism spectrum disorders. J Neural Transm. 2004 Jul;111(7):891–902. [PubMed]
65. Mouridsen SE, Rich B, Isager T, Nedergaard NJ. Psychiatric disorders in the parents of individuals with infantile autism: a case-control study. Psychopathology. 2007;40(3):166–171. [PubMed]
66. Daniels JL, Forssen U, Hultman CM, et al. Parental psychiatric disorders associated with autism spectrum disorders in the offspring. Pediatrics. 2008 May;121(5):e1357–1362. [PubMed]
67. Larsson HJ, Eaton WW, Madsen KM, et al. Risk factors for autism: perinatal factors, parental psychiatric history, and socioeconomic status. Am J Epidemiol. 2005 May 15;161(10):916–925. discussion 926-918. [PubMed]
68. Clegg J, Hollis C, Mawhood L, Rutter M. Developmental language disorders--a follow-up in later adult life. Cognitive, language and psychosocial outcomes. J Child Psychol Psychiatry. 2005 Feb;46(2):128–149. [PubMed]
69. Campbell M, Geller B, Small AM, Petti TA, Ferris SH. Minor physical anomalies in young psychotic children. Am J Psychiatry. 1978 May;135(5):573–575. [PubMed]
70. Impagnatiello F, Guidotti AR, Pesold C, et al. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15718–15723. [PubMed]
71. Vorstman JA, Morcus ME, Duijff SN, et al. The 22q11.2 deletion in children: high rate of autistic disorders and early onset of psychotic symptoms. Journal of the American Academy of Child and Adolescent Psychiatry. 2006 Sep;45(9):1104–1113. [PubMed]
72. Consortium TAGP. Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet. 2007;39:319–328. [PubMed]
73. Cohen D, Lazar G, Couvert P, et al. MECP2 mutation in a boy with language disorder and schizophrenia. Am J Psychiatry. 2002 Jan;159(1):148–149. [PubMed]
74. Blackwood DH, Fordyce A, Walker MT, St Clair DM, Porteous DJ, Muir WJ. Schizophrenia and affective disorders--cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am J Hum Genet. 2001 Aug;69(2):428–433. [PubMed]
75. Friedman JI, Vrijenhoek T, Markx S, et al. CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsy. Mol Psychiatry. 2008 Mar;13(3):261–266. [PubMed]
76. Alarcon M, Abrahams BS, Stone JL, et al. Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene. Am J Hum Genet. 2008 Jan;82(1):150–159. [PubMed]
77. Arking DE, Cutler DJ, Brune CW, et al. A common genetic variant in the neurexin superfamily member CNTNAP2 increases familial risk of autism. Am J Hum Genet. 2008 Jan;82(1):160–164. [PubMed]
78. Wedenoja J, Loukola A, Tuulio-Henriksson A, et al. Replication of linkage on chromosome 7q22 and association of the regional Reelin gene with working memory in schizophrenia families. Mol Psychiatry. 2007 Aug 7; [PubMed]
79. Shifman S, Bhomra A, Smiley S, et al. A whole genome association study of neuroticism using DNA pooling. Mol Psychiatry. 2008 Mar;13(3):302–312. [PubMed]
80. Skaar DA, Shao Y, Haines JL, et al. Analysis of the RELN gene as a genetic risk factor for autism. Mol Psychiatry. 2005 Jun;10(6):563–571. [PubMed]
81. Akbarian S, Huang HS. Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res Rev. 2006 Sep;52(2):293–304. [PubMed]
82. Addington AM, Gornick M, Duckworth J, et al. GAD1 (2q31.1), which encodes glutamic acid decarboxylase (GAD67), is associated with childhood-onset schizophrenia and cortical gray matter volume loss. Mol Psychiatry. 2005 Jun;10(6):581–588. [PubMed]
83. Straub RE, Lipska BK, Egan MF, et al. Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression. Mol Psychiatry. 2007 Sep;12(9):854–869. [PubMed]
84. Yip AG, McKee AC, Green RC, et al. APOE, vascular pathology, and the AD brain. Neurology. 2005 Jul 26;65(2):259–265. [PubMed]
85. Fatemi SH. The role of Reelin in pathology of autism. Mol Psychiatry. 2002;7(9):919–920. [PubMed]